Asco 2025 · Posters · Cáncer de Pulmón · Guzman Alonso, MD Volver

Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors.

Abstract: 8598
Poster Bd #: 78
Descargar Poster

Guzman Alonso, MD

Vall d'Hebron Institute of Oncology (VHIO).

Una iniciativa científica de: Eco Logo
Clover sgm Logo
Con el patrocinio de: Regeneron Logo